In pancreatic cancer, pelareorep previously demonstrated a strong efficacy signal when administered with gemcitabine, nab-paclitaxel and atezolizumab. Our new safety data indicate its ability to also ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

The stock market can be a scary place for those who aren’t prepared. Our writer outlines three ways we might avoid getting caught out.

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...

Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended Keytruda's coming loss of exclusivity can be managed.

British drug maker GSK on Monday said it will buy US biopharmaceutical company IDRx for up to $1.15 billion. The Boston-based biotechnology firm is developing therapeutics for the treatment of ...

A Goodwin Procter team has advised on British pharmaceutical giant GSK’s $1.15 billion acquisition of a US biopharmaceutical ...

GSK on Monday also announced a $1 billion deal to acquire another privately held cancer drug developer, IDRx. The agreement ...